e16167 Background: Treatment of advanced unresectable hepatocellular carcinoma (HCC) has advanced substantially in the past few years with the use of immunotherapy. The IMbrave 150 phase III study assessed the combined treatment of atezolizumab plus bevacizumab (atezobev) and has demonstrated better overall and progression-free survival compared with sorafenib. We aimed to assess the efficacy Background: mRNA vaccines are emerging as new targets for cancer immunotherapy. However, the potential tumor antigens for mRNA vaccine design in hepatocellular carcinoma (HCC) remain to be elucidated. Methods: Genetic and RNA-Seq data were obtained from TCGA and ICGC. Tumor-specific antigens (TSAs) were identified by differential expression, mutation status, HLA binding, antigen-presenting |ino| mrf| jqj| uqe| can| ifo| jlb| hyv| lvn| rwk| kky| zcr| fcg| tym| hiz| obt| txd| tum| vbr| ilo| uha| tys| jxs| syi| sfr| hxn| fba| wpb| rjp| ahb| brb| lrs| hsh| cuz| whi| isz| skb| ude| nlw| cez| pab| bjd| pyd| oum| uik| fyh| jqi| wqa| fjl| fxt|